These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis]. Tang X; Guo X; Sun LY; Ai Y; Yang X; Sun JJ; Wu JR; Gao J Zhongguo Dang Dai Er Ke Za Zhi; 2018 Apr; 20(4):290-294. PubMed ID: 29658453 [TBL] [Abstract][Full Text] [Related]
5. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505 [TBL] [Abstract][Full Text] [Related]
6. Association between clinicopathologic characteristics and BRAF Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596 [TBL] [Abstract][Full Text] [Related]
7. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020. Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688 [TBL] [Abstract][Full Text] [Related]
8. BRAF-V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first-line therapy. Wang CJ; Zhu T; Zhao CZ; Cui H; Wang D; Zhao ZJ; Huang XT; Li HL; Liu FF; Zhang R; Li ZG; Cui L Pediatr Blood Cancer; 2024 Sep; 71(9):e31099. PubMed ID: 38845144 [TBL] [Abstract][Full Text] [Related]
9. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan. Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047 [TBL] [Abstract][Full Text] [Related]
11. High Prevalence of Liu X; Zhang Y; Zhou CX Int J Surg Pathol; 2019 Dec; 27(8):836-843. PubMed ID: 31203679 [TBL] [Abstract][Full Text] [Related]
12. [Status of Langerhans cell histiocytosis in children and adults]. Kudo K Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857 [TBL] [Abstract][Full Text] [Related]
13. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations. Tran G; Huynh TN; Paller AS J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340 [TBL] [Abstract][Full Text] [Related]
14. Wang CJ; Cui L; Ma HH; Wang D; Zhang L; Lian HY; Li WJ; Zhang Q; Wang TY; Li ZG; Zhang R Mol Cancer Ther; 2021 Jul; 20(7):1316-1323. PubMed ID: 33879554 [TBL] [Abstract][Full Text] [Related]
15. Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry. Méhes G; Irsai G; Bedekovics J; Beke L; Fazakas F; Rózsa T; Kiss C Am J Surg Pathol; 2014 Dec; 38(12):1644-8. PubMed ID: 25118810 [TBL] [Abstract][Full Text] [Related]
16. BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay. Tatsuno M; Shioda Y; Iwafuchi H; Yamazaki S; Iijima K; Takahashi C; Ono H; Uchida K; Okamura O; Matubayashi M; Okuyama T; Matsumoto K; Yoshioka T; Nakazawa A Diagn Pathol; 2016 Apr; 11():39. PubMed ID: 27094161 [TBL] [Abstract][Full Text] [Related]
17. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases. Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021 [TBL] [Abstract][Full Text] [Related]